Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present GlaxoSmithKline plc (NYSE: GSK).

Full DD Report for GSK

You must become a subscriber to view this report.


Recent News from (NYSE: GSK)

Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September
Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices....
Source: SeekingAlpha
Date: September, 12 2018 14:40
CytoDyn Inc.'s (CYDY) New HIV Treatment Could Bring a Paradigm Shift in HIV Therapy
PRO 140 requires one dose a week, rather than daily pills Treatment has shown hardly any side-effects in clinical trials, while current HIV therapies may cause mild to severe side-effects CytoDyn’s treatment is simple for patients to administer with hardly any toxicity Signifi...
Source: NetworkNewsWire
Date: September, 11 2018 11:00
China Goes To The WTO (Wall Street Breakfast Podcast)
Today's Top Stories: China asks for WTO sanctions on the US, oil prices climb higher, and Renesas buys IDTI. Click play to listen in your browser. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (f...
Source: SeekingAlpha
Date: September, 11 2018 09:09
Wall Street Breakfast: China Requests WTO Sanctions Against U.S.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). China will ask the World Trade Organization to impose sanctions on the U.S. next week for non-compliance related to a...
Source: SeekingAlpha
Date: September, 11 2018 07:17
Urovant Sciences files for IPO of up to $150M
Urovant Sciences has filed for its initial public offering . More news on: Urovant Sciences, Astellas Pharma, Inc. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: September, 10 2018 18:59

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1439.3239.3339.4839.211,677,827
2017-02-0239.2639.3039.42539.132,763,200
2017-02-0139.5939.4639.5939.153,575,325
2017-01-3138.7839.3139.3538.773,490,735
2017-01-3038.7739.0039.0138.683,700,370

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1021,444116,01018.4846Cover
2018-12-0788,348212,53641.5685Short
2018-12-06113,756255,47444.5274Short
2018-12-04194,039374,38951.8282Short
2018-12-03595,2161,136,00552.3955Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GSK.


About GlaxoSmithKline plc (NYSE: GSK)

Logo for GlaxoSmithKline plc (NYSE: GSK)

Not available

 

Contact Information

 

 

Current Management

  • JeanPierre Garnier / CEO
  • John Coombe / CFO
  • Simon Bicknell / Secretary

Current Share Structure

     


    Recent Filings from (NYSE: GSK)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 12 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 10 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 10 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 04 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 30 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 30 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 24 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 15 2018

     

     


    Daily Technical Chart for (NYSE: GSK)

    Daily Technical Chart for (NYSE: GSK)


    Stay tuned for daily updates and more on (NYSE: GSK)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NYSE: GSK)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GSK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GSK and does not buy, sell, or trade any shares of GSK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/